Company News 09 May 2025 Orthocell US Remplir™ Sales Rollout Gains Pace with 12 Distributors Now Appointed Covering 21 States Orthocell has appointed 12 US distributors for its nerve repair product Remplir™, well ahead of the expected target of 10… Orthocell
Company News 30 Apr 2025 Orthocell Secures Health Canada Approval for Remplir™ in US$75 million Canadian Market Orthocell has secured a Medical Device Licence from Health Canada for Remplir™, opening access to the US$75 million Canadian nerve… Orthocell
Company News 28 Apr 2025 Orthocell Receives Regulatory Approval to Commence Sales of Remplir™ in US$84 million Thai market Orthocell has been granted a licence by the Food and Drug Administration of Thailand to commence sales of Remplir™ into… Orthocell
Company News 24 Apr 2025 Orthocell Appoints its First Four US Remplir™ Distributors Orthocell has appointed four US distributors for its flagship nerve repair product Remplir™, enabling the commencement of commercial distribution into… Orthocell
Company News 09 Apr 2025 Orthocell Receives Regulatory Approval for Striate+ in Brazil Orthocell has announced that Brazilian Health Regulatory Agency, ANVISA, has granted regulatory approval for the Company’s market-leading dental membrane, Striate+™,… Orthocell
Company News 04 Apr 2025 US FDA grants 510(k) clearance for Orthocell’s flagship Remplir™ nerve repair product Orthocell has announced that the US Food and Drug Administration has granted regulatory clearance under the 510(k) pathway for the… Orthocell
Company News 26 Mar 2025 First Sales of Striate+™ in DACH Region Orthocell has today announced that our exclusive global distribution partner BioHorizons has officially completed first sales of Orthocell’s dental product,… Orthocell
Company News 18 Mar 2025 Orthocell Receives Regulatory Approval for Striate+ in Singapore Orthocell has received regulatory approval from Singapore's Health Sciences Authority (HSA) for its market leading dental guided bone regeneration product,… Orthocell
Company News 21 Feb 2025 Thailand Regulatory Application for Remplir™ Orthocell has submitted a regulatory application to the FDA of Thailand to commence sales of its groundbreaking nerve repair device… Orthocell
Company News 03 Feb 2025 Orthocell Submits Canada Regulatory Application to Commence Sales of Remplir™ into US$75million Canadian market Orthocell has announced it has submitted an application to Health Canada for a Medical Device Licence (MDL) to sell its… Orthocell
